-
1Academic Journal
Συγγραφείς: A. A. Naumenko, D. O. Gromova, N. V. Trofimova, I. S. Preobrazhenskaya, А. А. Науменко, Д. О. Громова, Н. В. Трофимова, И. А. Преображенская
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 8, No 4 (2016); 91-97 ; Неврология, нейропсихиатрия, психосоматика; Vol 8, No 4 (2016); 91-97 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2016-4
Θεματικοί όροι: когнитивно-моторный тренинг, cerebral amyloidosis, basic symptomatic treatment, central acetylcholinesterase inhibitors, NMDA receptor blockers, akatinol memantine, gantenerumab, nootropic therapy, cerebrolysin, non-drug exposures, cognitive-motor training, церебральный амилоидоз, базисное симптоматическое лечение, ингибиторы центральной ацетилхолинэстеразы, блокаторы NMDA-рецепторов, акатинол мемантин, гантенерумаб, нооторопная терапия, церебролизин, нелекарственные методы воздействия
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/680/619; Гаврилова СИ, Федорова ЯБ, Колыхалов ИВ и др. Терапевтический потенциал Церебролизина в превентивной терапии болезни Альцгеймера. Журнал неврологии и психиатрии им. С.С. Корсакова. 2008;(8): 24-9. [Gavrilova SI, Fedorova YaB, Kolykhalov IV, et al. The therapeutic potential of Cerebrolysin in the preventative treatment of Alzheimer's disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;(8):24-9. (In Russ.)].; Гусев ЕИ, Гехт АБ, Белоусов ЮБ и др. Клинические и фармакоэкономические особенности применения Церебролизина в восстановительном лечении ишемического инсульта. Журнал неврологии и психиатрии им. С.С.Корсакова. 2007;(10):26-33. [Gusev EI, Gekht AB, Belousov YuB i dr. Clinical and pharmacoeconomic peculiarities of application of Cerebrolysin in rehabilitation of ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2007;(10):26-33. (In Russ.)].; Захаров ВВ, Яхно НН. Нарушения памяти. Москва: ГЭОТАР-Медиа; 2001. 160 с. [Zakharov VV, Yakhno NN. Narusheniya pamyati [Memory impairments]. Moscow: GEOTAR-Media; 2001. 160 p.]; Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi:10.1517/14712598.2011.578573. Epub 2011 Apr 20.; Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции. Руководство для врачей. 3-е издание. Москва: МЕДпресс-информ; 2011. С. 53-75. [Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii. Rukovodstvo dlya vrachei [Dementia. A guide for physicians]. 3rd edition. Moscow: MEDpress-inform; 2011. P. 53-75.]; Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007 Feb 13;68(7):501-8. Epub 2006 Oct 25.; Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 224 с. [Parfenov VA, Zakharov VV, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive impairments]. Moscow: Remedium; 2014. 224 p.]; Преображенская ИС, Громова ДО. Некоторые аспекты терапии нейродегенеративных деменций. Медицинский совет. 2014;(10):36-42. [Preobrazhenskaya IS, Gromova DO. Some aspects of the therapy of neurodegenerative dementia. Meditsinskii sovet. 2014;(10):36-42. (In Russ.)].; Brickman AM, Siedlecki KL, Stern Y. Cognitive and Brain reserve. In: Depp CA, Jeste DV, editors. Successful Cognitive and Emotional Aging. Arlington: American Psychiatric Publishing, Inc; 2010. P. 157-72.; Erickson KI, Colcombe SJ, Wadhwa R, et al. Training-induced plasticity in older adults: effects of training on hemispheric asymmetry. Neurobiol Aging. 2007 Feb;28(2):272-83. Epub 2006 Feb 9.; Chan D, Fox NC, Scahill RI, et al. Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol. 2001 Apr;49(4):433-42.; Dickerson BC, Goncharova I, SullivanMP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001 Sep-Oct;22(5): 747-54.; Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRImeasures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002 Apr 23;58(8):1188-96.; Scahill RI, Schott JM, Stevens JM, et al. Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluidregistered serial MRI. Proc Natl Acad Sci USA. 2002 Apr 2;99(7):4703-7.; Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-59.; Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006213. doi:10.1101/cshperspect.a006213.; Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan;9(1):119-28. doi:10.1016/S1474-4422(09)70299-6.; Whitwell JL. Longitudinal imaging: change and causality. Curr Opin Neurol. 2008 Aug;21(4):410-6. doi:10.1097/WCO.0b013e32830719d4.; Toyn JH, Rowley A, Matsuoka Y, et al. γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease? Int JAlzheimers Dis. 2013;2013:849128. doi:10.1155/2013/849128. Epub 2013 Apr 18.; Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther. 2010 Jul;10(7):1121-30. doi:10.1517/14712598.2010.493872.; Novakovic D, Feligioni M, Scaccianoce S, et al. Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Drug Des Devel Ther. 2013 Nov 13;7:1359-64. doi:10.2147/DDDT.S53401.eCollection 2013.; Vellas B, Carrillo MC, Sampaio C, et al; EU/US/CTAD Task Force Members. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul;9(4):438-44. doi:10.1016/j.jalz.2013.03.007.; Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci. 2008 Dec 24;28(52):14156-64. doi:10.1523/JNEUROSCI.4147-08.2008.; Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012 Feb;69(2):198-207. doi:10.1001/archneurol.2011.1538.Epub2011 Oct 10.; Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 2002 May;1(1):3.; Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med. 2004 Oct;10(10):1055-63.; Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008 Mar 4;148(5):370-8.; Oertel W, Ross JS, Eggert K, et al. Rationale for transdermal drug administration in Alzheimer's disease. Neurology. 2007 Jul 24;69(4 Suppl 1):S4-9.; Alvarez XA, Cacabelos R, Laredo M, et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol. 2006 Jan;13(1):43-54.; Rockenstein E, Adame A, Mante M, et al. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin. J Neural Transm (Vienna). 2005 Feb;112(2):269-82. Epub 2004 Jul 7.; Rockenstein E, Torrance M, Mante M, et al. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. J Neurosci Res. 2006 May 15;83(7): 1252-61.; Gauthier S, ProaЦo JV, Jia J, et al. Cerebrolysin in Mild-to-Moderate Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-47. doi:10.1159/000377672. Epub 2015 Mar 26.; Wey ZH, He QB, Wang H, et al. Metaanalysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm (Vienna). 2007;114(5):629-34. Epub 2007 Feb 23.; Weiner MW. Commentary on «Diagnosis of Alzheimer's disease: two decades of progress.» Central role of technology in the treatment and prevention of Alzheimer's disease. Alzheimers Dement. 2005 Oct;1(2):112-3.; Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults a meta-analytic study. Psychol Sci. 2003 Mar; 14(2):125-30.; Gates N, Fiatarone Singh MA, Sachdev PS, Valenzuela M. The effect of exercise training on cognitive function in older adults with mild cognitive impairment: a meta-analysis of randomized controlled trials. Am J Geriatr Psychiatry. 2013 Nov;21(11):1086-97. doi:10.1016/j.jagp.2013.02.018. Epub 2013 Jul 3.; Rodakowski J, Saghafi E, Butters MA, Skidmore ER. Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review. Mol Aspects Med. 2015 Jun-Oct;43-44: 38-53. doi:10.1016/j.mam.2015.06.003.Epub 2015 Jun 10.; Kawashima R. Mental Exercises for Cognitive Function: Clinical Evidence. J Prev Med Public Health. 2013 Jan;46 Suppl 1:S22-7. doi:10.3961/jpmph.2013.46.S.S22. Epub 2013 Jan 30.; Rozzini L, Costardi D, Chilovi BV, et al. Efficacy of Cognitive Rehabilitation in Patients with Mild Cognitive Impairment Treated with Cholinesterase Inhibitors. 4th ed. JohnWiley & Sons; 2007. P. 356-60.; Yates LA, Orrell M, Spector A, Orgeta V. Service users' involvement in the development of individual Cognitive Stimulation Therapy (iCST) for dementia: a qualitative study. BMC Geriatr. 2015 Feb 6;15:4. doi:10.1186/s12877-015-0004-5.; Boripuntakul S, Kothan S, Methapatara P, et al. Short-Term Effects of Cognitive Training Program for Individuals with Amnestic Mild Cognitive Impairment: a Pilot Study. 2nd ed. Taylor & Francis; 2012. P. 138-49.; van Paasschen J, Clare L, Yuen KS, et al. Cognitive rehabilitation changesmemory-related brain activity in people with Alzheimer disease. Neurorehabil Neural Repair. 2013 Jun;27(5):448-59. doi:10.1177/1545968312471902. Epub 2013 Jan 31.; Belleville S, Bherer L. Biomarkers of cognitive training effects in aging. Curr Transl Geriatr Exp Gerontol Rep. 2012 Apr 19;1(2): 104-110. Print 2012 Jun.; Baker LD, Frank LL, Foster-Schubert K, et al. Effects of Aerobic Exercise on Mild Cognitive Impairment: A Controlled Trial. Arch Neurol. 2010 Jan;67(1):71-9. doi:10.1001/archneurol.2009.307.; Suzuki T, Shimada H, Makizako H, et al. Effects of multicomponent exercise on cognitive function in older adults with amnesticmild cognitive impairment: a randomized controlled trial. BMC Neurol. 2012 Oct 31;12:128. doi:10.1186/1471-2377-12-128.; Schmidt W1, Endres M, Dimeo F, Jungehulsing GJ. Train the vessel, gain the brain: physical activity and vessel function and the impact on stroke prevention and outcome in cerebrovascular disease. Cerebrovasc Dis. 2013;35(4):303-12. doi:10.1159/000347061. Epub 2013 Apr 10.